scholarly journals Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection

JAMA ◽  
2022 ◽  
Author(s):  
Anna Wald
Keyword(s):  
Booster Vaccination

Reduction of Milk Contamination with Aflatoxin-M1 through Vaccination of Dairy Cattle with Aflatoxin-B1 Vaccine

2020 ◽  
Keyword(s):  
Dairy Cattle ◽  
Aflatoxin B1 ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Nano Particles ◽  
Aflatoxin M1 ◽  
Serum Samples ◽  
Serum Albumins ◽  
Milk Contamination ◽  
Before And After

Aflatoxin M1 is one of mycotoxin derivatives, which is secreted in milk of dairy cattle fed on feed contaminated with Aflatoxin-B1 (AFB1). The current study was designed to prepare a vaccine against AFB1and to evaluate its efficacy in reducing or preventing secretion of AFM1 in milk. Aflatoxin-B1 was prepared, purified and transformed into oxime, then it was fixed on bovine serum albumins. The AFB1-BSA conjugate was adjuvanted with Gold Nano particles then Montanide ISA 206. The prepared vaccine was used for immunization of rabbits by S/c routes as 100 µg/dose and dairy cattle by I/M routes as 500 µg/dose. The vaccinated animals were boosted at 3 weeks post primary immunization. Serum samples were collected and examined for the anti-AFB1 using AGPT. A mean titer of 15.2 AGPU/ml was detected at 2 weeks post primary vaccination then significantly increased till reached to 76.8 AGPU/ml at 6 weeks post Booster vaccination. All vaccinated rabbits were challenged with dose of 0.3 mg AFB1 toxin/Kg. The vaccinated rabbit showed 100% protection and no AFB1 toxin residue was detected in their livers. Milk samples were collected from non-vaccinated and AFB1-immunized dairy cattle then examined with ELISA for quantitation of AFM1 residues before and after vaccination. The results showed that the prepared AFB1 vaccine was safe, potent and able to reduce AFM1 release in milk of vaccinated heifers by 70%. So the vaccination of lactating animals with the AFB1vaccine might represent a valid tool for the prevention of AFM1 contamination of milk and dairy products.

scholarly journals Corrigendum to ‘Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom’

EBioMedicine ◽  
2021 ◽  
Vol 68 ◽  
pp. 103420
Author(s):  
Pauline Versteegen ◽  
Marta Valente Pinto ◽  
Alex M. Barkoff ◽  
Pieter G.M. van Gageldonk ◽  
Jan van de Kassteele ◽  
...  
Keyword(s):  
Older Adults ◽  
United Kingdom ◽  
The Netherlands ◽  
Collaborative Study ◽  
Booster Vaccination ◽  
The United Kingdom

scholarly journals Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 501
Author(s):  
Chung-Jong Kim ◽  
Ji-Yun Bae ◽  
Kang-Il Jun ◽  
Hae-Sun Chung ◽  
Aeyeon Kim ◽  
...  
Keyword(s):  
Booster Vaccination ◽  
Healthcare Personnel ◽  
Testing Time ◽  
Seroprevalence Rate ◽  
Mmr Vaccine ◽  
Igg Antibody ◽  
Seropositivity Rate ◽  
History Of ◽  
Measles Vaccination ◽  
Measles Incidence

We aimed to identify the presence of the measles IgG antibody (mIgG-Ab) in healthcare personnel and finding out who needs the measles vaccination. The history of measles vaccination was obtained from the national vaccine registry. A baseline mIgG-Ab test was performed, and the measles vaccine was administered to participants who tested negative or equivocal for mIgG-Abs. During the study, 2885 (87.3%) of the 3303 employees were tested for measles serostatus. The baseline seropositivity rate for mIgG-Abs was 91.9%. Among the 234 seronegative cases, 82.9% were born after 1985. The seroprevalence rate was lower in those who received the measles–mumps–rubella (MMR) vaccine >10 years before the testing time, especially if they were born after 1985 and if there was only one previous record of vaccination. Among the 234 seronegative cases, MMR vaccination was administered in 174 cases, of which serostatus was evaluated in 146 cases. After the first dose, positive seroconversion was achieved in 126 participants (86.3%). After a second dose, 15 achieved (75.0%) positive seroconversion. In healthcare personnel born after the period when measles incidence significantly decreased, it may be necessary to reassess their immune status for measles if more than 10 years have elapsed since the last vaccination.

Booster vaccination against HBV unnecessary before age 15 years?

2003 ◽  
Vol &NA; (1378) ◽  
pp. 16
Author(s):  
&NA;
Keyword(s):  
Booster Vaccination

Impact of Acellular Pertussis Preschool Booster Vaccination on Disease Burden of Pertussis in The Netherlands

2008 ◽  
Vol 27 (3) ◽  
pp. 218-223 ◽  
Author(s):  
Sabine C. de Greeff ◽  
Frits R. Mooi ◽  
Joop F. P. Schellekens ◽  
Hester E. de Melker
Keyword(s):  
The Netherlands ◽  
Disease Burden ◽  
Booster Vaccination

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

Vaccine ◽  
2010 ◽  
Vol 28 (3) ◽  
pp. 849-857 ◽  
Author(s):  
Isabel Leroux-Roels ◽  
François Roman ◽  
Sheron Forgus ◽  
Cathy Maes ◽  
Fien De Boever ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Vaccine ◽  
Booster Vaccination ◽  
Primary Study ◽  
Double Blind ◽  
H5n1 Influenza

Seroprevalence ofBordetella pertussisin the Mexican population: a cross-sectional study

2013 ◽  
Vol 142 (4) ◽  
pp. 706-713 ◽  
Author(s):  
C. CONDE-GLEZ ◽  
E. LAZCANO-PONCE ◽  
R. ROJAS ◽  
R. DeANTONIO ◽  
L. ROMANO-MAZZOTTI ◽  
...  
Keyword(s):  
Socioeconomic Status ◽  
Disease Burden ◽  
Public Health Intervention ◽  
Booster Vaccination ◽  
Cross Sectional Study ◽  
Serum Samples ◽  
Nutrition Survey ◽  
Cross Sectional ◽  
Health And Nutrition ◽  
Sources Of Infection

SUMMARYSerum samples collected during the National Health and Nutrition survey (ENSANUT 2006) were obtained from subjects aged 1–95 years (January–October 2010) and analysed to assess the seroprevalence ofBordetella pertussis(BP) in Mexico. Subjects' gender, age, geographical region and socioeconomic status were extracted from the survey and compiled into a subset database. A total of 3344 subjects (median age 29 years, range 1–95 years) were included in the analysis. Overall, BP seroprevalence was 47·4%. BP seroprevalence was significantly higher in males (53·4%,P = 0·0007) and highest in children (59·3%) decreasing with advancing age (P = 0·0008). BP seroprevalence was not significantly different between regions (P = 0·1918) and between subjects of socioeconomic status (P = 0·0808). Women, adolescents and young adults were identified as potential sources of infection to infants. Booster vaccination for adolescents and primary contacts (including mothers) for newborns and infants may provide an important public health intervention to reduce the disease burden.

scholarly journals Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

1981 ◽  
Vol 87 (2) ◽  
pp. 201-209 ◽  
Author(s):  
N. Masurel ◽  
P. Ophof ◽  
P. de Jong
Keyword(s):  
New Jersey ◽  
Side Effects ◽  
Antibody Response ◽  
Virus Vaccine ◽  
Influenza A ◽  
H1n1 Virus ◽  
Vaccine Dose ◽  
Booster Vaccination ◽  
Booster Immunization ◽  
Group A

SummaryA group of 269 pupils of the Harbour and Transport Training Institute in Rotterdam (group A), aged 13–20 years, and of 109 patients of the Dr Mr Willem van den Bergh Foundation at Noordwijk (group B), aged 11–21 years, were immunized with a whole virus vaccine containing 10, 20, or 40 μg HA of A/USSR/92/77 (H1N1) influenza virus. A booster vaccination was administered 6 weeks later with 20 μg HA of the same virus. Many of the participants had been immunized during the two preceding years with a whole virus vaccine containing A/New Jersey/8/76 (H1N1) (A/NJ/76) virus. The side-effects, mostly of a moderate nature, increased with the dose of virus in the vaccine. In group A side effects were least frequent in the vaccinees who had never received A/NJ/76 vaccine. A single dose of A/USSR/77 vaccine did not produce satisfactory levels of homologous antibodies. After booster immunization with 20 μg HA of A/USSR/77 virus participants showed a higher homologous antibody response in all vaccine-dose groups if they had not been immunized with A/NJ/76 virus in previous years. After primary and especially after booster immunization with A/USSR/77 virus, a very high response against A/NJ/76 virus and adequate levels of A/NJ/76 antibody were found in participants who had been immunized previously with A/NJ/76 virus. Those who had not been immunized with this virus previously showed no or a very low antibody response to A/NJ/76 virus.

Sign in / Sign up

Export Citation Format

Share Document